Daré Bioscience Statistics
Total Valuation
Daré Bioscience has a market cap or net worth of $27.58 million. The enterprise value is $22.24 million.
Important Dates
The next estimated earnings date is Thursday, March 27, 2025, after market close.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Daré Bioscience has 8.70 million shares outstanding. The number of shares has increased by 16.28% in one year.
| Current Share Class | 8.70M |
| Shares Outstanding | 8.70M |
| Shares Change (YoY) | +16.28% |
| Shares Change (QoQ) | +0.69% |
| Owned by Insiders (%) | 1.59% |
| Owned by Institutions (%) | 8.81% |
| Float | 8.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.01 |
| Forward PS | 8.63 |
| PB Ratio | -18.58 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.14
| Current Ratio | 1.14 |
| Quick Ratio | 0.89 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -66.79% |
| Return on Invested Capital (ROIC) | -1,243.91% |
| Return on Capital Employed (ROCE) | -469.80% |
| Revenue Per Employee | $72,358 |
| Profits Per Employee | -$138,645 |
| Employee Count | 26 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.89% in the last 52 weeks. The beta is 1.32, so Daré Bioscience's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | -22.89% |
| 50-Day Moving Average | 3.20 |
| 200-Day Moving Average | 3.69 |
| Relative Strength Index (RSI) | 50.64 |
| Average Volume (20 Days) | 25,672 |
Short Selling Information
The latest short interest is 87,561, so 1.01% of the outstanding shares have been sold short.
| Short Interest | 87,561 |
| Short Previous Month | 91,458 |
| Short % of Shares Out | 1.01% |
| Short % of Float | 1.02% |
| Short Ratio (days to cover) | 4.50 |
Income Statement
In the last 12 months, Daré Bioscience had revenue of $1.88 million and -$3.60 million in losses. Loss per share was -$0.43.
| Revenue | 1.88M |
| Gross Profit | -19.76M |
| Operating Income | -23.03M |
| Pretax Income | -28.87M |
| Net Income | -3.60M |
| EBITDA | -22.99M |
| EBIT | -23.03M |
| Loss Per Share | -$0.43 |
Full Income StatementBalance Sheet
The company has $11.23 million in cash and $5.89 million in debt, giving a net cash position of $5.34 million or $0.61 per share.
| Cash & Cash Equivalents | 11.23M |
| Total Debt | 5.89M |
| Net Cash | 5.34M |
| Net Cash Per Share | $0.61 |
| Equity (Book Value) | -1.48M |
| Book Value Per Share | -0.17 |
| Working Capital | 1.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$8.01 million and capital expenditures -$617,528, giving a free cash flow of -$8.63 million.
| Operating Cash Flow | -8.01M |
| Capital Expenditures | -617,528 |
| Free Cash Flow | -8.63M |
| FCF Per Share | -$0.99 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,224.40% |
| Pretax Margin | -191.61% |
| Profit Margin | -191.61% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Daré Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.28% |
| Shareholder Yield | -16.28% |
| Earnings Yield | -13.07% |
| FCF Yield | -31.29% |
Analyst Forecast
The average price target for Daré Bioscience is $20.33, which is 541.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.33 |
| Price Target Difference | 541.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 134.46% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on July 1, 2024. It was a reverse split with a ratio of 0.0833333:1.
| Last Split Date | Jul 1, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0833333:1 |
Scores
Daré Bioscience has an Altman Z-Score of -16.02 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.02 |
| Piotroski F-Score | 3 |